Garfunkel Wild, P.C., a premier law firm with a specialty in health law, is pleased to announce the arrival of Elisabeth A. Pimentel as a partner in the firm’s Health Care and Corporate Practice Groups. Ms. Pimentel who will be based in the firm’s Connecticut office joins from Wiggin and Dana, LLP.

“Growing our Health Care and Corporate practice in Connecticut – and nationwide – has been an ongoing strategic focus for us,” said Garfunkel Wild Chairman, Andrew Blustein.  “Lis’ experience working on a variety of corporate and regulatory issues for health care providers will be a great addition to our multi-disciplinary health care team.”

Ms. Pimentel brings experience advising clients with respect to mergers, acquisitions, and affiliations, medical foundations, and professional services and employment agreements. Her regulatory practice encompasses certificate of need matters, licensure issues, and counseling nonprofit organizations with governance and tax-exemption questions.

Ms. Pimentel will re-unite with former colleague Merton G. Gollaher who joined Garfunkel Wild in 2019. “Lis’ arrival bolsters our strong health care team and will help us continue to meet clients’ needs for sophisticated counsel with a commitment to quality and value,” said Mr. Gollaher. “I am excited to share Garfunkel Wild’s culture with Lis which enables individuals to learn and grow while fostering collaboration and team work. I am confident the opportunity to collaborate with an impressive set of attorneys across many diverse practice specialties in Connecticut and elsewhere will take her practice to the next level and provide the best possible service to her clients.”

The appointment of Ms. Pimentel further illustrates the firm’s continued focus on strategic planning, including attorney development and growth into new markets and practice areas. “Chambers USA 2021 nearly doubled our firm’s Health Care Practice rankings, recognizing for the first time our practice in Connecticut, in addition to New York and New Jersey,” said Mr. Blustein. “This recognition speaks to the experience, knowledge and reputation of our Health Care attorneys in every office and reflects our commitment to serving the needs of the health care industry at the highest level and to attracting top talent like Lis to our firm.”

Prior to private practice, Ms. Pimentel was a judicial intern for the Honorable Alfred V. Covello, Senior United States District Judge for the District of Connecticut, and for six years was an officer in the United States Navy where she conducted research in the field of medical education and simulation-based training technology.

Ms. Pimentel received her J.D. with high honors and an intellectual property certificate from The University of Connecticut School of Law where she was the Business Manager for the Connecticut Law Review.  She received her B.A. in chemistry with a concentration in cell molecular biology from Colby College.

Click Here to read her biography.

 

Salvatore Puccio and Jean Krebs, co-authored the article “Avoiding Pandemic Predicaments: Be ready to navigate the changing landscape brought on by COVID-19,” published in the May 2021 edition of Outpatient Surgery Magazine.

The article discusses how centers should prepare for continued COVID-related legal challenges as lingering restrictions brought on by the pandemic are lifted. The workplace is now different, both in appearance and in the rules that govern it. The article identifies three ongoing issues you will likely need to manage in the coming months.

Click Here to read the article.

 

 

Garfunkel Wild continues to increase its Healthcare practice and lawyer recognition in Chambers USA 2021 annual rankings of the foremost law firms and lawyers in the country. Chambers & Partners conducts research that includes thousands of interviews with clients and peers, and determines rankings based on select criteria, including legal knowledge, experience, client service and effectiveness.

In the latest Chambers USA 2021 legal directory, Chambers cited a wide range of client and competitor feedback on Garfunkel Wild including:

  • “Their excellence encompasses strategy, knowledge, managing regulatory relationships, teamwork approach and client management.”
  • “Their advice in addressing regulatory, licensing and insurance-related concerns are among the best I have encountered,” says one client. “The attorneys are responsive and collaborative with a client-centric focus that is at the heart of their practice.”
  • “They have a strong healthcare practice. They are very responsive and give good advice. Very competent and skilled.”

Garfunkel Wild’s 2021 rankings include:

PRACTICE

Healthcare (New York, New Jersey and Connecticut)

LAWYERS

Healthcare (New York)

  • Robert Andrew Wild
  • Judith Eisen

Healthcare (New Jersey)

  • Andrew E. Blustein
  • Jeffrey S. Brown
  • Julia P. Belton

Healthcare (Connecticut)

  • Barry B. Cepelewicz
  • Merton G. Gollaher

 

Garfunkel Wild, P.C., a premier law firm with a specialty in health law, is pleased to announce the formal launch of the firm’s multi-disciplinary Cannabis Law Practice Group to help clients navigate the rapidly evolving cannabis landscape and conflicting federal, state and local laws and regulations. The group is comprised of attorneys representing every practice of the firm including partner Jim Dering who, prior to joining Garfunkel Wild, worked on the implementation of New York State’s Medical Marijuana Program in his previous position as General Counsel of the New York State Department of Health. The group will focus on cannabis and CBD issues in states where it regularly practices including New York, New Jersey and Connecticut.

“Our cannabis group was formed to meet the legal needs of employers, health care professionals, entrepreneurs, cultivators, distributors, retailers, investors and others dealing with a broad range of regulatory and legal issues in this space,” said Andrew Blustein, Chairman of Garfunkel Wild. “That includes health care, real estate, venture capital, financing, labor and employment, intellectual property, licensing and regulatory compliance.”

With more than 40 years of experience representing organizations in highly regulated fields, Garfunkel Wild’s cross-industry attorneys are uniquely qualified to counsel clients across the full spectrum of cannabis-related legal issues.

“We have been providing cannabis-related legal counsel to clients in the cannabis industry and elsewhere, as well as conducting webinars, podcasts and writing legal alerts on the topic, for many years,” said Jim Dering. “The recent expansion of cannabis legislation — legalizing recreational marijuana — made it the right time to formally assemble and announce the group’s interdisciplinary capabilities.”

 

In a major win for 340B covered entities, which includes among others certain hospitals and, FQHCs, the Health Resources and Services Administration (HRSA) sent letters on May 17, 2021 to six pharmaceutical manufacturers informing them that they could no longer restrict 340B pricing to covered entities that use contract pharmacies.  Covered entities are permitted under the 340B program to dispense 340B-discounted drugs through their own pharmacies or through contracts with outside pharmacies.  Starting last year, these manufacturers began taking actions that limited covered entities’ access to discounted drugs through the 340B program. Some stopped providing the 340B discount price for products dispensed through contract pharmacies, while others limited sales by requiring onerous data submissions or proof of 340B compliance.

HRSA’s letters stated that the manufacturers’ actions have resulted in overcharges and are in direct violation of the 340B statute. The manufacturers must immediately begin offering covered outpatient drugs at the 340B discount price to covered entities through their contract pharmacy arrangements and repay covered entities for the overcharges.  These manufacturers also may be subject to civil monetary penalties (CMPs) of up to $5,000 for each instance of overcharging under the 340B Program Ceiling Price and Civil Monetary Penalties final rule.  HRSA warned that continued violations would result in additional CMPs.

* * * * *

Should you have any questions regarding the above or if your facility has been denied 340B discounts by any manufacturer and you need assistance, please contact the Garfunkel Wild attorney with whom you regularly work, or contact us at info@garfunkelwild.com.

Click Here to download the Legal Alert.